E
Eunice L. Kwak
Researcher at Harvard University
Publications - 148
Citations - 24080
Eunice L. Kwak is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & FOLFIRINOX. The author has an hindex of 49, co-authored 146 publications receiving 21705 citations.
Papers
More filters
Journal ArticleDOI
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
Dejan Juric,Johann S. de Bono,Patricia LoRusso,John Nemunaitis,Elisabeth I. Heath,Eunice L. Kwak,Teresa Macarulla Mercadé,Elena Geuna,Maria Jose de Miguel-Luken,Chirag Patel,Keisuke Kuida,Serap Sankoh,Eric H. Westin,F. Zohren,Yaping Shou,Josep Tabernero +15 more
TL;DR: Intermittent dosing of TAK-117 had an acceptable safety profile and enabled higher doses and total weekly exposures versus once-daily dosing, and the potential for Tak-117 as single-agent therapy appears limited.
Journal ArticleDOI
Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC).
Sai-Hong Ignatius Ou,Yung-Jue Bang,D. Ross Camidge,Gregory J. Riely,Ravi Salgia,Geoffrey I. Shapiro,Benjamin Solomon,Jeffrey A. Engelman,Eunice L. Kwak,Jeffrey W. Clark,L. Tye,Keith D. Wilner,Patricia Stephenson,Marileila Varella-Garcia,Kristin Bergethon,Anthony J. Iafrate,Alice T. Shaw +16 more
TL;DR: Detailed efficacy and safety data are presented for crizotinib in patients with advanced ROS1-rearranged NSCLC, and ROS1 status was determined by break-apart FISH assays.
Journal ArticleDOI
Targeted Agents: The Rules of Combination
TL;DR: An overview of the MTAs that have emerged as Food and Drug Administration–approved drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic effect.
Journal ArticleDOI
Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors
Geoffrey I. Shapiro,Eunice L. Kwak,J. Baselga,Jordi Rodon,Christian Scheffold,A. D. Laird,C. Bedell,Gerald Edelman +7 more
TL;DR: Exposure to XL147 reduced levels of phosphorylated PI3K pathway components in PBMCs, hair, skin, and tumor tissues in an exposure-dependent manner and was generally well tolerated with the MTD for the 21/7 schedule defined as 600 mg.
Journal ArticleDOI
A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Robert R. McWilliams,Andrew H. Ko,E. Gabriela Chiorean,Eunice L. Kwak,Heinz-Josef Lenz,Paul I. Nadler,Debra L. Wood,Masamoto Fujimori,Kohei Morita,Tetsuhi Inada,Hiroyuki Kouji +10 more
TL;DR: A first-in-class cAMP-response element-binding protein (CBP)/β-catenin modulator that induces stem cell differentiation and increases p300 in pre-clinical models is presented.